Cargando…

COVID-19 vaccine equity in Africa

The coronavirus disease 2019 (COVID-19) pandemic has dominated global health discourse since early 2020. By early 2021, the unprecedented speed of vaccine development against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by government, academia and industry contributed biotechnolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Turyasingura, Natasha, James, Wilmot G, Vermund, Sten H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235805/
https://www.ncbi.nlm.nih.gov/pubmed/36622662
http://dx.doi.org/10.1093/trstmh/trac130
_version_ 1785052772169678848
author Turyasingura, Natasha
James, Wilmot G
Vermund, Sten H
author_facet Turyasingura, Natasha
James, Wilmot G
Vermund, Sten H
author_sort Turyasingura, Natasha
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic has dominated global health discourse since early 2020. By early 2021, the unprecedented speed of vaccine development against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by government, academia and industry contributed biotechnological tools to reduce severe COVID-19 infections, hospitalizations and deaths. However, vaccine distribution has not been equitable. We address one element of this challenge, namely the low COVID-19 vaccination rates in African countries, which lag behind higher-income nations. We evaluate key obstacles to initiatives addressing this inequity and emphasize Africa-based research and development as a sustainable solution to ensuring vaccine equity in Africa.
format Online
Article
Text
id pubmed-10235805
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102358052023-06-03 COVID-19 vaccine equity in Africa Turyasingura, Natasha James, Wilmot G Vermund, Sten H Trans R Soc Trop Med Hyg Commentary The coronavirus disease 2019 (COVID-19) pandemic has dominated global health discourse since early 2020. By early 2021, the unprecedented speed of vaccine development against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by government, academia and industry contributed biotechnological tools to reduce severe COVID-19 infections, hospitalizations and deaths. However, vaccine distribution has not been equitable. We address one element of this challenge, namely the low COVID-19 vaccination rates in African countries, which lag behind higher-income nations. We evaluate key obstacles to initiatives addressing this inequity and emphasize Africa-based research and development as a sustainable solution to ensuring vaccine equity in Africa. Oxford University Press 2023-01-09 /pmc/articles/PMC10235805/ /pubmed/36622662 http://dx.doi.org/10.1093/trstmh/trac130 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Commentary
Turyasingura, Natasha
James, Wilmot G
Vermund, Sten H
COVID-19 vaccine equity in Africa
title COVID-19 vaccine equity in Africa
title_full COVID-19 vaccine equity in Africa
title_fullStr COVID-19 vaccine equity in Africa
title_full_unstemmed COVID-19 vaccine equity in Africa
title_short COVID-19 vaccine equity in Africa
title_sort covid-19 vaccine equity in africa
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235805/
https://www.ncbi.nlm.nih.gov/pubmed/36622662
http://dx.doi.org/10.1093/trstmh/trac130
work_keys_str_mv AT turyasinguranatasha covid19vaccineequityinafrica
AT jameswilmotg covid19vaccineequityinafrica
AT vermundstenh covid19vaccineequityinafrica